×
About 11,517,752 results

An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences
https://stories.gilead.com/articles/an-open-letter-from-daniel-oday-june-22

After receiving the green light from the FDA to move forward, Gilead is about to start trials of an inhaled version of remdesivir. We will screen healthy volunteers for Phase 1 trials this week and hope to begin studies in patients with COVID-19 in August. If the trials are successful, this could represent important progress. Remdesivir, our investigational antiviral medicine, is currently give...

Association of Circadian Abnormalities in Older Adults With an Increased Risk of Developing Parkinson Disease
https://jamanetwork.com/journals/jamaneurology/article-abstract/2767087

Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation in COVID-19
https://www.rheumatology.org/Portals/0/Files/ACR-COVID-19-Clinical-Guidance-Summary-MIS-C-Hyperinflammation.pdf

COVID-19 Clinical Guidance for Pediatric Patients with Rheumatic Disease
https://www.rheumatology.org/Portals/0/Files/COVID-19-Clinical-Guidance-Summary-for-Pediatric-Patients-with-Rheumatic-Disease.pdf

COVID-19, hypothalamo-pituitary-adrenal axis and clinical implications
https://link.springer.com/content/pdf/10.1007/s12020-020-02325-1.pdf

Managing common endocrine disorders amid COVID-19 pandemic
https://www.sciencedirect.com/science/article/pii/S1871402120301697

Determinants of COVID-19 disease severity in patients with cancer
https://www.nature.com/articles/s41591-020-0979-0

Antibody Detection and Dynamic Characteristics in Patients with COVID-19
https://watermark.silverchair.com/ciaa461.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAABEYwggRCBgkqhkiG9w0BBwagggQzMIIELwIBADCCBCgGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQML-2UYyGMp5__74HZAgEQgIID-VP47852zLLsLFFHC7k2obWGvI27loF7mFx6ccaQRjbwhuQIGLnPxwfOQMeFlfFVAFZAKa4ln4Zu8tJ4pyMAe_0DpNoBtNd7J4G248ZywRygT0RWAeDM9E0oxYYaVyNIeQYIseOEQYJljSdOjlMeT7rTXn_bjWG0XgnM4hcKG5vdzeeNaCMClYAUcNlvEL_JhqOEsouWaE1P2B6rwqyTQFevO_P6IUOHYMipr0kA7hT7Ei4R5HE-BRVNatcJs-QWZFqwXdbArSLOVckkOr84O73LZ9FLbR5nLxG59zI_JfXk_xBxRbftrCAY82kgfXjxdLd6WtGY-zDY52Y_gWhhwd3JZ9gZaBX9zxT_0V9epseHguRBD3_DNexdrwZ2RhzcN6GxeRTnJORFqFEB-0haDPa3s7zgZtQJtEzYGzo3380CI2d0J1GZeI8tZNGHhwvdKAxrpqb6oSYjIH41u6eLPgQwoyg6DAJISSL8pfDZWcc5ILKQYGy4HMlL9PqKv2J8Py1NaFNHiTPFlPN6VbRBGUxT_dWyspgerDc3V6bD2Spr6Q68vQEgz1L4eF9DOWDLKrCmBC00e2m7kMAGQ9PXPGalQBCNClMflQvj4s4itOfBrdOxfMgRb2jeVcK0wv28oBg0L4a1mxhUbBb6vVY4AqAwBgMaxZxxHxyBfRJBdWr3bk3S8ow5-UAFEXFxMwShRR3Wp5wxiZ5kv_hs4ZW8ycXC-Lc77qCSHqpgGl3qFJsakyjlalhF1AUMNo7Suj6HtWtYUKiQHe3hgZiFI6T9Up8hIhYPkoQNKd3v5jmzZl0YF7oEeqrOVoD6mOC5tRBnY1EE1eS53CHCCuCpxwEkES6BWHb-P0YzfM4SSpQlNCXZUxxHXnlmWZoNz9KVqXL-zm6x7dlG7Qd-hjsFoN4wn8h_THDZh3XgbL2CGCnKkRVBYJuMhz7iavKFHzogXUfP0U9zGcYLYS1wDBvTrkEU94n3sHbZejRFqQ14dVg-A3cep6o4d8H8p5mw1AvkSzp-s-NR2tjiJ66nTR9v_urbFGMSnlfo8lk5HH3DtZUG1KHCx0Lp626rmX0IXV2SxetMQCV7AXLRHmG-xa_67N74Lmkiqho2p6RkYiKtrkTZ-6h8ykKhwa0DfdbB1FrDRADlwOk8CnaUfNeiWtw82AoyQjWP6BMkIxgm-mZ3hV7heeH0RB73ES7OLUR2C1R2hyyt21cSo2Ub0jugp9-Gk5asCWsi8XKK7bubNP3D7vD0N2VdLkO1ZT969XyveN0soj5BYAbe7XMzPuf8dA8JfX86duPXjnnPG4qrvRS2NhaObrb-M_t5xa2VxIlTYcXNlnmTpkV7VnSyTqki_w

The antibodies against SARS-CoV-2 can be detected in the middle and later stage of the COVID-19. Antibody detection may play an important role in the diagnosis of COVID-19 as complement approach for viral nucleid acid assays.

Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery
https://www.nejm.org/doi/full/10.1056/NEJMc070348
The New England Journal of Medicine;

Previous studies have demonstrated that IgG and neutralizing antibodies against coronavirus associated with the severe acute respiratory syndrome (SARS) may persist, in spite of a decline in titer, for 2 years in patients who have recovered from SARS.

Emergency Restraining Order and Injunctive Relief against Landmark Hospital of Athens
https://img.medscapestatic.com/article/932/722/20-06-17-Landmark-_COMP_FSC.pdf

This action seeks immediate court intervention to stop Defendant Landmark Hospital from concealing and mishandling a COVID-19 outbreak in their facility, and to prevent Defendant Landmark from receiving patients into their facility or discharging or transferring patients out of their facility.

Hospitals won't release number of workers with COVID-19; nurses union urges transparency
https://www.10tv.com/article/news/local/hospitals-wont-release-number-workers-covid-19-nurses-union-urges-transparency-2020-apr/530-39d6033b-9ec9-4ea4-8307-3f90e3194c3a

Amid push toward transparency, several Portland-area hospitals won’t disclose coronavirus patient tallies
https://www.oregonlive.com/coronavirus/2020/03/amid-push-toward-transparency-several-portland-area-hospitals-wont-disclose-coronavirus-patient-tallies.html

Fraudulent Coronavirus Disease 2019 (COVID-19) Products
https://www.fda.gov/consumers/health-fraud-scams/fraudulent-coronavirus-disease-2019-covid-19-products

The U.S. Food and Drug Administration is issuing warning letters to firms for selling fraudulent products with claims to prevent, treat, mitigate, diagnose or cure coronavirus disease 2019 (COVID-19). We are actively monitoring for any firms marketing products with fraudulent COVID-19 prevention and treatment claims. The FDA is exercising its authority to protect consumers from firms selling un...

There are so many coronavirus myths that even Snopes can’t keep up
https://www.washingtonpost.com/media/2020/04/15/coronavirus-misinformation-snopes/

COVID-19 Myths vs. Realities
https://www.jhsph.edu/covid-19/articles/coronavirus-facts-vs-myths.html

The swiftly moving novel coronavirus continues its relentless spread around the world, upending life as we know it and creating a breeding ground for misinformation. Some rumors are harmless, while others can be dangerous, stoking fear and threatening health. Here, we separate true from false, based on the best science and expertise available.

The Greek study in the effects of colchicine in COVID-19 complications prevention (GRECCO-19 study): Rationale and study design
https://www.sciencedirect.com/science/article/pii/S1109966620300610

Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. GRECCO-19 will be a prospective, randomized, open-labeled, controlled study to assess the effects of colch...

Colchicine as a possible therapeutic option in COVID-19 infection
https://link.springer.com/article/10.1007/s10067-020-05247-5

In contrast, we consider that colchicine can be a good therapeutic option because of several effects in the immunology system involved in SARS-CoV-2 infection and in the acute respiratory distress syndrome (ARDS). Colchicine has effects on the chemotaxis of inflammatory cells such as neutrophils and monocytes and on the intracellular transportation of vesicles such as endosomes and exosomes.

SARS‐CoV‐2 viral spike G614 mutation exhibits higher case fatality rate
https://onlinelibrary.wiley.com/doi/full/10.1111/ijcp.13525
The International Journal of Clinical Practice;

The COVID‐19 pandemic is caused by infection with the SARS‐CoV‐2 virus. The major mutation detected to date in the SARS‐CoV‐2 viral envelope spike protein, which is responsible for virus attachment to the host and is also the main target for host antibodies, is a mutation of an aspartate (D) at position 614 found frequently in Chinese strains to a glycine (G). We sought to infer health impact o...

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity
https://www.scripps.edu/_files/pdfs/news-and-events/The D614G mutation in the SARS-CoV-2 spike protein reduces S1.pdf

SARS coronavirus 2 (SARS-CoV-2) isolates encoding a D614G mutation in the viral spike (S) protein predominate over time in locales where it is found, implying that this change enhances viral transmission. We therefore compared the functional properties of the S proteins with aspartic acid (SD614) and glycine (SG614) at residue 614. We observed that retroviruses pseudotyped with SG614 infect...

Mutated coronavirus shows significant boost in infectivity
https://www.scripps.edu/news-and-events/press-room/2020/20200612-choe-farzan-coronavirus-spike-mutation.html

A tiny genetic mutation in the SARS coronavirus 2 variant circulating throughout Europe and the United States significantly increases the virus’ ability to infect cells, lab experiments performed at Scripps Research show.